XTANDI® is an androgen receptor inhibitor used for the treatment of 4 types of advanced prostate cancer. See Important Safety Info, Risks, & Benefits.
subclassification of mCRPC tissues using AR and the neuroendocrine marker synaptophysin (SYP) expression assessed by IHC, most patients with high or heterogeneous STEAP1 and PSMA expression had AR-positive prostate cancer (AR+/SYP- or AR+/SYP+) while those with no PSMA expression had AR-null pr...
a possible indicator of prostate cancer—everything changed. I went to see the urologist, had a biopsy and found out I had moderately aggressive prostate cancer. Back then, hearing the “C” word—cancer—was like getting a death sentence. I ...
Researchers also wanted to know if this made a difference in how long patients lived without the cancer spreading to other parts of their body. What were the results? Researchers found that patients with a large decline in PSA level after treatment were more likely to live longer and without ...
While the concept of immunotherapy for cancer has been proposed for many years, proof of principle did not exist. In the context of prostate cancer, the allogeneic cell based agent, GVAX has been tested. GVAX consists of a platform of ir... PW Kantoff - 《Annals of Oncology》 被引量: ...
VASN has been identified as an oncogene in various cancers, such as glioma [24], thyroid cancer [25], and prostate cancer [26]. However, its role in rectal cancer metastasis, especially in lung metastasis, has not been explored, and our study reports this phenomenon and the potential ...
Seth Wander, MD, PhD on novel anti-estrogen therapies that could expand treatment options in estrogen receptor–positive advanced breast cancer.
colorectal or prostate cancer via detecting CTC.199Kafshgari et al. generated magnetic TNTs by incorporating a ferrofluid containing iron oxide NPs (diameter ~10 nm) in planar weakly-connected TNTs sheets.200Post-annealing, the TNTs were loaded with camptothecin and cultured with HeLa cells. ...
Magnetic hyperthermia has been approved for clinical use in Europe, and clinical registration for prostate cancer treatment in the United States has completed [90]. Despite these advances, magnetic hyperthermia still suffers from some critical drawback. For instance, it requires the need for ...
[169,170]. Prostate carcinoma cells bind AGEs through the V-domain of RAGE [171]. AGEs have in fact been identified in cancerous tissue, which leads to the possibility of AGE activation of RAGE contributing to cancer growth [172]. However there are also other RAGE ligands in greater ...